Charu Aggarwal, MD, MPH

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858
Headshot of Charu Aggarwal, MD, MPH
Penn Medicine Provider

About me

  • Physician Leader, Airways Malignancies Research
  • Director, Precision Oncology Innovation, Penn Center for Cancer Care Innovation
  • Section Chief, Head & Neck and Thoracic Cancers, Hematology-Oncology
  • Leslye M. Heisler Professor for Lung Cancer Excellence

Dr. Aggarwal specializes in the management of patients with lung cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches.

My education and training

  • Medical School: Lady Hardinge Medical College
  • Residency: Buffalo General Medical Center
  • Fellowship: Fox Chase Cancer Center

Reviews

Average Rating

197 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
March 2026
dr aggarwal is the best
Anonymous
March 2026
shes a great physician
Anonymous
February 2026
dr agarwal is kind , caring and smart and considerate. every time she sees me she gives me a hug
Anonymous
February 2026
took time to address my questions and concerns

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Aggarwal is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Voruganti T, Wang X, Davis C, Martella AO, Marmarelis ME, Aggarwal C. Illusion of Comprehensive Testing in Non-Small Cell Lung Cancer: Why Coverage, Sensitivity, and Reporting Matter , JCO Oncol Pract: 2026

Jantus-Lewintre E, Calabuig-Fariñas S, Gandara D, Raez L, Leighl NB, Fusco N, Khorshid O, Mayo de Las Casas C, Reduzzi C, Urum Y, Aggarwal C, Serrano MJ, Rolfo C, Malapelle U. Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy , J Liq Biopsy, 12: 2026,100462

Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME. Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) , Lung Cancer: 2026

Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL. Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers , Mol Ther: 2026

Aggarwal C, Ng S, Kamalakar R, Beruti S, Simmons A, Beasley MB. A United States-Based Real-World Study on Biomarker Testing and Rebiopsy Rates Among Patients With Non-Small Cell Lung Cancer Across Lines of Therapy , Clin Lung Cancer: 2026

Adam Barsouk, Maxim Yaskolko, Jonathan H. Sussman, Lova Sun, Roger B. Cohen, Charu Aggarwal, Corey J. Langer, Melina E. Marmarelis Sotorasib vs adagrasib in the 2L+ setting: Outcomes in a large, multi-institutional, real-world database of KRAS-G12C mutated mNSCLC. , J Clin Oncol: 2026

Phurin Areesawangkit, Adam Barsouk, Maxim Yaskolko, Lucy Wang, Cole Friedes, Roger B. Cohen, Lova Sun, Charu Aggarwal, Melina E. Marmarelis, Aditi P. Singh, Kyle W. Robinson, Christopher D'Avella, Christine A. Ciunci, Steven J. Feigenberg, Jeffrey D. Bradley, Nikhil Yegya-Raman, Michelle Iocolano, Christiana Davis, Corey J. Langer Long-term survival outcomes of consolidative local ablative therapy after response to first-line systemic treatment in oligometastatic NSCLC. , J Clin Oncol: 2026

Michelle A. Worst, Andrew Small, Amy Furedy, Charu Aggarwal, Sandip P. Patel The impact of online CME on addressing clinical decision-making for immunotherapy in advanced squamous NSCLC. , J Clin Oncol: 2026

Xavier Orcutt, Vivek Nimgaonkar, Lova Sun, Charu Aggarwal, Aaron B. Cohen, Ronac Mamtani, Qi Long, Ravi B. Parikh Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab. , J Clin Oncol: 2026

Rachel Jaber Chehayeb, Willdragon Wang, Lova Sun, Aditi P. Singh, Roger B. Cohen, Corey J. Langer, Charu Aggarwal, Melina E. Marmarelis Incidentally discovered lung cancer in explanted lungs at the time of lung transplantation: Management and outcomes. , J Clin Oncol: 2026